Aura Biosciences, Inc. is a pharmaceutical company based in the United States that focuses on developing ESG-friendly precision immunotherapies for various solid tumors while prioritizing the sustainability of organs affected by cancer. With a medium risk rating score of 27.4, the company's lead candidate, bel-sar, is in late-stage clinical development for treating primary choroidal melanoma and other ocular oncology indications, along with early-stage development for bladder cancer. Aura Biosciences operates exclusively in the U.S. and is committed to promoting environmental, sustainability, and governance practices in its operations.